<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927173</url>
  </required_header>
  <id_info>
    <org_study_id>CTP-0001-00</org_study_id>
    <secondary_id>IL-MOH-HTA-4860</secondary_id>
    <nct_id>NCT00927173</nct_id>
  </id_info>
  <brief_title>Evaluation of the Brainsway Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression Disorder</brief_title>
  <official_title>A Prospective Multicenter Double Blind Randomized Controlled Trial to Explore the Tolerability, Safety and Efficacy of the H-Coil Deep Transcranial Magnetic Stimulation (TMS) in Subjects With Major Depression Disorder (MDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brainsway</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brainsway</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of deep brain rTMS,
      (Transcranial Magnetic Stimulation), a new experimental procedure using the H-Coil, in
      subjects with Major Depressive Disorder that have been previously unsuccessfully treated with
      antidepressant medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, randomized double blind, sham controlled study to evaluate the
      safety and efficacy of H-coil deep transcranial magnetic stimulation (dTMS) as a treatment
      for patients with major depressive disorder who have been previously unsuccessfully treated
      with antidepressant medications. Studies of repetitive transcranial magnetic stimulation
      (rTMS), typically using a figure-8 coil, have shown that stimulating superficial brain
      regions can be beneficial in treating major depression. Differing from traditional figure-8
      coil, the H-coil is designed to stimulate deep brain regions related to motivation, reward,
      and pleasure. Preliminary studies have been conducted and seem to indicate that through
      stimulating certain brain areas with the H-coil, dTMS may have an antidepressant effect. The
      study population will consist of patients with major depressive disorder who have failed
      adequate medication treatment or shown significant intolerance to medications. The study
      duration is 18 weeks, with a 2 week period of weaning the patient off medication, followed by
      4 weeks of 5 daily treatments and 12 weeks of biweekly treatments. Mood and mental state will
      be carefully monitored through standard psychological scales and rating during the drug
      taper-down and throughout treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HDRS-21</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission rates</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">233</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Deep Transcranial Magnetic Stimulation treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Brainsway H-Coil Deep TMS System</intervention_name>
    <description>Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Brainsway H-Coil Deep TMS System (Sham treatment)</intervention_name>
    <description>In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.</description>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients.

          -  Men and women 22-68 years of age.

          -  Primary DSM-IV diagnosis of Major Depression, single or recurrent episode.

          -  Current depressive episode is less than 5 years duration.

          -  The patient did not respond to at least one but not more than four antidepressant
             treatments in the current episode.

          -  Patients who have not completed antidepressant trials due to intolerance to therapy of
             2 or more anti-depressant medications in the current episode.

          -  Satisfactory safety screening questionnaire for transcranial magnetic stimulation.

          -  Patients not suffering from hypo or hyper-thyroidism based on pre-study TSH level or
             medically stabilized.

          -  Patients able to tolerate psychotropic medication washout and no psychotropics during
             the treatment, other than benzodiazepine at equivalent daily dose of up to 3 mg
             lorazepam.

        Exclusion Criteria:

          -  A history of schizophrenia, any psychotic disorder, PTSD, bipolar disorder, OCD,
             eating disorders (e.g., anorexia nervosa, bulimia) or substance abuse

          -  A history of panic disorder, social anxiety disorder or personality disorder (such as
             antisocial, schizotypal, histrionic, borderline, narcissistic) as assessed by the
             investigator to be primary, causing a higher degree of distress or impairment than
             MDD.

          -  A history of any significant medical disease (i.e., cardiovascular, gastrointestinal,
             etc.)

          -  A history of seizures, at risk for seizure (e.g., history of significant head trauma
             with loss of consciousness for greater than or equal to 5 minutes or familial or
             personal history of epilepsy) or have been diagnosed with a seizure disorder.

          -  Undergone rTMS treatment, Vagus Nerve Stimulation, or Deep Brain Stimulation.

          -  Received ECT within the last 3 months or failed to respond to ECT treatment.

          -  Individuals with a significant neurological disorder or insult including:

               -  Any condition likely to be associated with increased intracranial pressure

               -  Space occupying brain lesion

               -  Any history of seizure EXCEPT those therapeutically induced by ECT

               -  History of cerebrovascular accident

               -  Transient ischemic attack within two years

               -  Cerebral aneurysm

               -  Dementia

               -  Parkinson's disease

               -  Huntington's chorea

               -  Multiple sclerosis

          -  Individuals with hearing loss.

          -  Any intracranial implant such as aneurysm clips, shunts, stimulators, cochlear
             implants, or electrodes, or any other metal object within or near the head, excluding
             the mouth, that cannot be safely removed.

          -  A cardiac pacemaker, implanted medication pump, intracardiac line, or acute, unstable
             cardiac disease.

          -  Use of fluoxetine within 6 weeks of the randomization visit.

          -  Use of a Monoamine Oxidase Inhibitor (MAOI) within 2 weeks of the randomization visit.

          -  Present suicidal risk as assessed by the investigator.

          -  Implanted neurostimulators.

          -  History of abnormal MRI.

          -  If participating in psychotherapy, must have been in stable treatment for at least 3
             months prior to entry into the study, with no anticipation of change in the frequency
             of therapeutic sessions, or the therapeutic focus over the duration of the rTMS trial.

          -  Clinically significant laboratory abnormality, in the opinion of the Investigator
             based on CBC and biochemistry.

          -  Women of childbearing potential and not using a medically accepted form of
             contraception when engaging in sexual intercourse.

          -  Women: if pregnant, planning on becoming pregnant, or currently nursing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yechiel Levkovitz, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shalvat Mental Health Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abraham Zangen, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weizmann Institute of Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Center for Mind &amp; Brain</name>
      <address>
        <city>Sacramento and Davis</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smart Brain and Health</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Mental Health Care Inc. - Juno Beach</name>
      <address>
        <city>Juno Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Mental Health Care Inc. - Royal Palm Beach</name>
      <address>
        <city>Royal Palm Beach</city>
        <state>Florida</state>
        <zip>33411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLean Hospital - TMS Services</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Nashua Mental Health Center</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropharmacology Services</name>
      <address>
        <city>New-York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University / New York State Psychiatric Institute</name>
      <address>
        <city>New-York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Medical Center Department of Psychiatry &amp; Behavioral Sciences</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Uni. Of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senior Adults Specialty Research</name>
      <address>
        <city>Ausitn</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8898</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Addiction and Mental Health (CAMH)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EPS Ville-Evrard</name>
      <address>
        <city>Neuilly Sur Marne</city>
        <zip>93332</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universit채tsklinikum Bonn, Klinik und Poliklinik f체r Psychiatrie und Psychotherapie</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik f체r Psychiatrie und Psychotherapie, Ludwig-Maximilians-Universit채t</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beer Yaacov Mental Health Center</name>
      <address>
        <city>Beer Yaacov</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shalvata Mental Health Center</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadasah Ein-Karem Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kfar Shaul Mental Health Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2009</study_first_submitted>
  <study_first_submitted_qc>June 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2009</study_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TMS</keyword>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <keyword>MDD</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

